• Itraconazole: A Better Biofilm Assay Framework

  2026-08-16

  Itraconazole is a triazole antifungal agent with value beyond single-point susceptibility testing. This guide connects CYP3A4 interaction studies with PP2A–autophagy-driven Candida biofilm resistance to improve assay design and interpretation.

• TMEM16F in Kupffer Cells Protects Against Listeria

  2026-08-15

  The reference study identifies Kupffer cell-expressed TMEM16F as a critical determinant of host protection during Listeria monocytogenes infection, shifting the focus from T-cell membrane repair to liver-resident macrophages. Its findings connect plasma-membrane integrity with inflammatory control, liver injury, and metabolic disruption, providing a cell-specific framework for studying infection-associated tissue damage.

• ABT-737 Workflows for BCL-2-Dependent Apoptosis

  2026-08-15

  ABT-737 is a BH3 mimetic BCL-2 protein inhibitor for probing mitochondrial apoptosis, treatment resistance, and anti-apoptotic protein dependence. This workflow-oriented guide covers dose design, co-culture experiments, assay controls, and troubleshooting across lymphoma, leukemia, multiple myeloma, and solid-tumor models.

• Risedronate Sodium: FPPS Inhibition in Bone Research

  2026-08-14

  Risedronate Sodium is a bisphosphonate and FPP synthase inhibitor used to study osteoclast-mediated bone resorption inhibition. Peer-reviewed rat data support lung-targeted risedronate–vitamin D3 dendrimers as a preclinical strategy for improving exposure while reducing oral gastrointestinal limitations.

• Auranofin Workflows for Redox and Autophagy

  2026-08-14

  Build more informative cell assays with Auranofin, a thioredoxin reductase inhibitor that connects redox disruption to apoptosis, radiation response, and antimicrobial testing. A mechanics-aware workflow helps distinguish direct oxidative stress effects from cytoskeleton-dependent autophagy.

• Hyperoxia, Nrf2, and Ferroptosis in Intestinal Injury

  2026-08-13

  Liu et al. connect hyperoxia-induced intestinal epithelial injury with ferroptosis and identify Nrf2 as a regulatory node linking oxidative stress to inflammatory signaling. Their findings place the COX-2/PGE2/EP2 pathway downstream of ferroptotic damage, offering a mechanistic framework for studying oxygen-associated neonatal intestinal injury.

• Zoledronic Acid: Reproducible Cell Assays

  2026-08-13

  Learn how Zoledronic Acid, SKU A1352, can support better-controlled viability, proliferation, and apoptosis experiments. This scenario-based guide addresses concentration design, insolubility, storage, orthogonal readouts, and practical vendor selection.

• Lenalidomide (CC-5013): Mechanism & MM Research

  2026-08-12

  Lenalidomide (CC-5013) is an oral thalidomide derivative with immunomodulatory, anti-angiogenic, and direct antitumor activities. Its TNF-alpha secretion inhibition and emerging epigenetic synergy with DOT1L inhibition make it a useful compound for multiple myeloma research.

• Melittin B6628 for Reliable Cell Assays

  2026-08-12

  Melittin (SKU B6628) is a practical bioactive peptide tool for studying G protein signaling alongside viability, migration, and cell-death endpoints. This scenario-based guide explains how to prepare, control, and interpret Melittin experiments without confusing pathway modulation with nonspecific cytotoxicity.

• Resazurin Cell Viability Assay Kit for Bone Research

  2026-08-11

  Connect osteoblast biology with quantitative cell-health data using a sensitive, non-toxic readout for treatment screening. This workflow shows how to pair resazurin reduction with differentiation and mineralization endpoints when evaluating PORCN inhibition in sclerosteosis models.

• Porcupine Inhibition for Severe Sclerosteosis

  2026-08-10

  The 2025 Bone Research study identifies PORCN inhibition with LGK974 as a pharmacological strategy for reducing pathological Wnt activity and bone overgrowth in SOST-deficient models. Its combined osteoblast, osteoclast, gene-expression, mechanical-loading, and microcomputed tomography analyses support further investigation while highlighting sex-specific target engagement and important translational limitations.

• Methyl-β-cyclodextrin: Membrane Study Guide

  2026-08-09

  Methyl-β-cyclodextrin supports controlled membrane cholesterol extraction and related studies of lipid organization, membrane fluidity modulation, and cholesterol-dependent signaling. This guide covers preparation, controls, and troubleshooting; the reagent is for scientific research only and is not a diagnostic or therapeutic product.

• MK 0893: A Mechanism-First GCGR Assay Guide

  2026-08-08

  MK 0893 is a competitive, reversible glucagon receptor antagonist for dissecting GCGR signaling in diabetes models. This guide translates its allosteric binding mechanism and structural evidence into practical choices for binding, cAMP, selectivity, and in vivo assays.

• KR-12 Antimicrobial Peptides: Design and Applications

  2026-08-07

  The 2024 review of KR-12 presents this compact LL-37-derived peptide as a platform for combining antimicrobial activity with immune regulation, while surveying sequence, structural, formulation, and biomaterial-engineering strategies. Its main practical contribution is a design framework for improving potency, stability, biofilm activity, delivery, and tolerability without treating every engineered peptide as interchangeable.

• Unlocking Resistance: Meropenem Trihydrate in Translational

  2026-08-07

  Explore how Meropenem trihydrate is redefining antibiotic resistance research. This thought-leadership article blends mechanistic insights with strategic guidance for translational scientists, leveraging cutting-edge metabolomics and workflow strategies to bridge the gap between bench and bedside.

454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page